London
· Delayed Price · Currency is GBP · Price in USD CRISPR Therapeutics AG Statistics
Total Valuation
CRISPR Therapeutics AG has a market cap or net worth of GBP 3.06 billion. The enterprise value is 1.68 billion.
| Market Cap | 3.06B |
| Enterprise Value | 1.68B |
Important Dates
The next estimated earnings date is Friday, February 21, 2025.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.11% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 83.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.38 |
| EV / Sales | 10.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.75 |
Financial Position
The company has a current ratio of 21.64, with a Debt / Equity ratio of 0.12.
| Current Ratio | 21.64 |
| Quick Ratio | 21.55 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.19 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -13.07% and return on invested capital (ROIC) is -10.04%.
| Return on Equity (ROE) | -13.07% |
| Return on Assets (ROA) | -9.57% |
| Return on Capital (ROIC) | -10.04% |
| Revenue Per Employee | 371,820 |
| Profits Per Employee | -439,216 |
| Employee Count | 407 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.10% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.10% |
| 50-Day Moving Average | 45.48 |
| 200-Day Moving Average | 50.93 |
| Relative Strength Index (RSI) | 48.73 |
| Average Volume (20 Days) | 7,629 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.14 |
Income Statement
In the last 12 months, CRISPR Therapeutics AG had revenue of GBP 151.33 million and -178.76 million in losses. Loss per share was -2.16.
| Revenue | 151.33M |
| Gross Profit | -194.78M |
| Operating Income | -248.00M |
| Pretax Income | -176.43M |
| Net Income | -178.76M |
| EBITDA | -233.59M |
| EBIT | -248.00M |
| Loss Per Share | -2.16 |
Balance Sheet
The company has 1.44 billion in cash and 169.77 million in debt, giving a net cash position of 1.27 billion.
| Cash & Cash Equivalents | 1.44B |
| Total Debt | 169.77M |
| Net Cash | 1.27B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.45B |
| Book Value Per Share | 16.96 |
| Working Capital | 1.38B |
Cash Flow
In the last 12 months, operating cash flow was -140.88 million and capital expenditures -1.78 million, giving a free cash flow of -142.66 million.
| Operating Cash Flow | -140.88M |
| Capital Expenditures | -1.78M |
| Free Cash Flow | -142.66M |
| FCF Per Share | n/a |
Margins
Gross margin is -128.71%, with operating and profit margins of -163.88% and -118.13%.
| Gross Margin | -128.71% |
| Operating Margin | -163.88% |
| Pretax Margin | -116.59% |
| Profit Margin | -118.13% |
| EBITDA Margin | -154.36% |
| EBIT Margin | -163.88% |
| FCF Margin | n/a |
Dividends & Yields
CRISPR Therapeutics AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.11% |
| Shareholder Yield | -5.11% |
| Earnings Yield | -5.84% |
| FCF Yield | -4.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRISPR Therapeutics AG has an Altman Z-Score of 8.96.
| Altman Z-Score | 8.96 |
| Piotroski F-Score | n/a |